Magnolia Medical Technologies received an FDA warning letter for current good manufacturing practice violations affecting its Steripath Gen 2 blood collection system.
What happened
FDA inspected Magnolia Medical Technologies' medical device operations at 200 W. Mercer Street, Suite 500, Seattle, WA 98119 from June 3, 2021 through July 15, 2021. FDA found that the firm's corrective and preventive action (CAPA) procedures, design verification, and production process controls did not meet the Quality System regulation for the Steripath Gen 2 Blood Collection System. FDA said the firm's August 5, 2021 response was inadequate in several areas.
What FDA found
The firm did not keep complete records of CAPA meetings in its Corrective Action Report, as its own procedure required.
21 CFR 820.100(a)The firm did not investigate or document its evaluation of all three potential causes identified for premature retraction of butterfly retractable needles in CAPA C00046.
21 CFR 820.100(a)The firm closed a CAPA about incorrect instructions for use without adequately investigating and correcting all affected product lots, including lot 9448037 that was distributed with the incorrect instructions.
21 CFR 820.100(a)The firm did not conduct verification testing to support the shelf life of the Steripath Gen 2 with the butterfly needle inlet accessory.
21 CFR 820.30(f)The firm did not have manufacturing procedures to document and control the remaining shelf life of the butterfly needle inlet component when used to make the finished Steripath Gen 2 device.
21 CFR 820.70(a)The firm's CAPA C00055 did not include descriptions and records of its investigation into why labeling changes after FDA clearance for expanded indications were not implemented.
21 CFR 820.100(a)
What FDA wants
FDA asks the company to respond in writing within 15 business days with specific corrections, preventive actions, and documentation, and to explain how it will prevent recurrence. FDA also requests a conference call to discuss corrective actions for CAR C00046.
Who should pay attention
- medical device specification developers
- firms relying on suppliers for blood collection components
- quality teams managing CAPA, design verification, and shelf-life controls
This is a summary. Read the original letter on fda.gov.